French study tracks Dupilumab's Real-World impact on severe nasal polyps
NCT ID NCT06393946
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study follows 150 adults in France with severe chronic rhinosinusitis and nasal polyps who are already taking dupilumab (Dupixent®). Researchers will collect data on patient characteristics, disease history, and treatment patterns over two years. The goal is to see how the drug performs in everyday clinical practice, including changes in symptoms like nasal congestion and polyp size, as well as any side effects.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Dupilumab (Dupixent®)
- What this could lead to
- If successful, this study could provide real-world evidence on how well dupilumab works for severe nasal polyps in routine care, helping doctors optimize treatment.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be influenced by other factors. It only includes patients already prescribed dupilumab, limiting generalizability.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 150 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2023
- Expected to finish
-
Jul 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients with asthma initiating Dupilumab for their Severe chronic rhinosinusitis with nasal polyposis (CRSwNP) according to the prescribing information in France.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patient aged \>= 18 years old at the time of the initiation of the treatment with dupilumab (Dupixent®). * Decision to initiate Dupixent® prior to inclusion in the study, initiation of Dupixent® for severe Chronic rhinosinusitis with nasal polyposis (CRSwNP) maximum 3 months before inclusion. * Informed consent and willingness to participate. Exclusion Criteria: * Conditions or legal situations resulting in impossibility to consent or impacting the interpretation of the results. * Patient participating in an interventional clinical trial with experimental product at inclusion.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chronic rhinosinusitis with nasal polyposis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Investigational Site Number: 250.0001
Nantes, 44093, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.